Cerenome, Inc. (CNSY)
0.6427
-0.03
(-4.06%)
USD |
NASDAQ |
Nov 06, 16:00
0.6601
+0.02
(+2.71%)
After-Hours: 20:00
Cerenome Research and Development Expense (Quarterly) : 4.265M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.265M |
| March 31, 2026 | 2.865M |
| December 31, 2025 | 2.941M |
| September 30, 2025 | 2.436M |
| June 30, 2025 | 1.246M |
| March 31, 2025 | 1.756M |
| December 31, 2024 | 2.186M |
| September 30, 2024 | 2.858M |
| June 30, 2024 | 2.773M |
| March 31, 2024 | 2.763M |
| December 31, 2023 | 2.794M |
| September 30, 2023 | 2.493M |
| June 30, 2023 | 1.42M |
| March 31, 2023 | 2.983M |
| December 31, 2022 | 2.138M |
| September 30, 2022 | 2.945M |
| June 30, 2022 | 2.831M |
| March 31, 2022 | 1.785M |
| December 31, 2021 | 1.599M |
| September 30, 2021 | 1.491M |
| June 30, 2021 | 1.106M |
| March 31, 2021 | 1.127M |
| December 31, 2020 | 1.096M |
| September 30, 2020 | 0.336M |
| June 30, 2020 | 1.108M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.941M |
| December 31, 2019 | 1.729M |
| September 30, 2019 | 0.921M |
| June 30, 2019 | 1.289M |
| March 31, 2019 | 1.426M |
| December 31, 2018 | 1.636M |
| September 30, 2018 | 1.226M |
| June 30, 2018 | 1.267M |
| March 31, 2018 | 2.499M |
| December 31, 2017 | 2.394M |
| September 30, 2017 | 3.004M |
| June 30, 2017 | 2.992M |
| March 31, 2017 | 3.289M |
| December 31, 2016 | 2.863M |
| September 30, 2016 | 3.96M |
| June 30, 2016 | 5.247M |
| March 31, 2016 | 4.127M |
| December 31, 2015 | 4.629M |
| September 30, 2015 | 4.352M |
| June 30, 2015 | 6.048M |
| March 31, 2015 | 3.963M |
| December 31, 2014 | 2.999M |
| September 30, 2014 | 3.14M |
| June 30, 2014 | 4.674M |
| March 31, 2014 | 4.292M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| Ernexa Therapeutics, Inc. | 1.871M |
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| Anika Therapeutics, Inc. | 7.895M |
| Savara, Inc. | 21.95M |